CLAIM CARD
The evidence base reveals important tensions regarding the consistency and generalizability of cardiometabolic findings. While numerous studies report significant associations (Acosta 2019, Rosa 2024, Zhang 2025, Zhang 2025b), others present more nuanced or null findings. This suggests that in certain pathological states, the expected BAT-mediated metabolic benefits may be attenuated. Furthermore, the therapeutic development approach described in Cal 2025, involving a nitroalkene derivative of salicylate (SANA) that induces creatine-dependent thermogenesis, represents an alternative pharmacological strategy that does not rely on direct cold exposure. The heterogeneity in study designs—from human cohorts analyzing temperature rhythms to murine models of genetic obesity—highlights the need for careful interpretation when synthesizing evidence across different biological contexts and experimental paradigms.
Evidence grade: exploratory
Contradiction status: none
Publication: 5e04142b-5106-4483-8db7-d9378c53fb19
Provenance: Derivation Web chain
Citation Support
source_1Jaeckstein 2025source_2Ma 2025source_3Feng 2025source_4Kwok 2024source_5Lyons 2024